Aberrant DNA Methylation of FTH-1 and SHOX2 Contributes to Lung Cancer Progression

Salar Tahmasbi*, MD, Armin Sadeghi*, MD, Habib Zarredar*, PhD, Milad Asadi**, PhD, Shahryar Hashemzadeh*, MD, Venus Zafari**, PhD, Hamed Sabbagh-Jadid†, MD, Mortaza Raeisi***, MD

*Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
**Department of Basic Oncology, Health Institute, Ege University, Izmir, Turkey
***Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Background: Lung cancer is the most lethal malignancy in the world due to its poor prognosis. DNA methylation change has been identified as a valuable target for cancer, diagnosis, and prognosis. Ferritin heavy chain 1 (FTH-1) and SHOX homeobox 2 (SHOX2) DNA methylation were investigated in non-small cell lung cancer (NSCLC) as novel epigenetic biomarkers.

Method: In this case-control study, we initially evaluated the diagnostic value of FTH-1 and SHOX2 DNA methylation, and the Cancer Genome Atlas (TCGA) data on the methylation profile of NSCLC was analyzed. Whole DNA was extracted and bisulfite modification was performed. Then, the methylation status of FTH-1 and SHOX2 was evaluated using Quantitative Methylation Specific polymerase chain reaction (PCR) (qMSP). We used GraphPad Prism version 6.00 program for statistical analysis. Mann-Whitney U test (TCGA-LUNG), paired t-test (internal samples) and receiver operating characteristic (ROC) curve analysis were used to evaluate the statistical differences of DNA methylation between NSCLC tissues samples and adjacent normal specimens (P < 0.05, mean ± SD).

Results: TCGA and q-MSP results showed significant FTH-1 hypomethylation and SHOX2 hypermethylation in NSCLC tissues in comparison with margin specimens. Also, FTH-1 and SHOX2 methylation levels were significantly associated with the clinical stage of malignancy. Furthermore, The ROC curve analysis revealed that the area under the curve (AUC) values for FTH-1 and SHOX2 were determined to be 0.751 and 0.8676, respectively. This indicates the importance of FTH-1 and SHOX2 as diagnostic biomarkers for NSCLC.

Conclusion: This study indicates that FTH-1 and SHOX2 methylation could be promising targets for liquid biopsy application of lung cancer.

Keywords: DNA methylation, Epigenetic, Carcinoma, Non-small-cell lung
Introduction
In 2018, the World Health Organization (WHO) reported that lung cancer killed 2.0 million people. In recent years, efforts have been made to provide early detection of lung cancer by expanding screening in high-risk populations. The epigenetic events (like Abnormal DNA methylation), are a source of biomarkers for the screening, diagnosis, and prognosis of cancers that occur during carcinogenesis. Important roles of DNA methylation include regulating gene expression, epigenetic alterations, and maintaining cellular identity, which often occur in tumorigenesis.

Evidence shows that aberrant methylation happens through cancer progression in two ways: global hypomethylation and regional hypermethylation. DNA hypermethylation especially occurs in CpG islands within the promoter region of tumor suppressor genes in malignant cells, leading to post-transcriptional silencing of associated genes and subsequent tumor progression. Many studies have shown that DNA methylation abnormalities are also associated with the incidence and development of lung cancer. The aberrant methylation of certain genes in tumor tissues compared with normal ones suggests that dysregulation of these genes may be involved in tumor progression, invasion, and metastasis by modulating various mechanisms. Evidence illustrated that hypermethylation within the promoter region of SHOX2 (the short stature homeobox gene 2) is involved in its regulation and could serve as a potential diagnostic biomarker for lung cancer screening at early or advanced stages.

Subsequently, SHOX2 methylation has been under consideration in an increasing number of studies investigating its diagnostic value in lung cancer. Another gene that has been introduced as a novel biomarker for lung cancer is the FTH1 gene. It was shown that Ferritin-heavy polypeptide 1 is involved in various cellular processes, including cytokine signaling, adaptive immune system regulation, and cell death. Besides, FTH1 has been illustrated to bind high molecular weight kininogen (HKa) and repress its anti-angiogenic activity on epithelial cells during inflammation and tumor progression in vivo and in vitro. It was shown that FTH1 is downregulated through tumorigenesis, and functions as a tumor suppressor in non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer. However, FTH1 also shows oncogenic properties in metastatic melanoma cells. Therefore, given their significance through tumor progression, the present study aimed to evaluate whether SHOX2 and FTH-1 methylation levels could serve as valuable diagnostic targets for lung cancer.

Materials and Methods
Validation of FTH-1 and SHOX methylation in NSCLC samples
Preparation of patient samples
In the present case-control study, tissue samples were collected from 50 patients with lung cancer and 50 healthy people in Imam Reza Hospital for three years, from 2018 to 2021. All patients who participated in the present study were from the north-west population of Iran (Azarbaijan) (Table 1). Patients with radiotherapy or chemotherapy, tuberculosis history, or patients who refused to participate in the study were excluded. An informed written consent was obtained from all participants, and the lung tissues of participants were collected by bronchoscopy and needle biopsy techniques, as the routine parts of the patient diagnostic approach. Tissue samples were maintained in liquid nitrogen till DNA extraction was performed. This study was approved by the Ethical Committee of Tabriz University of Medical Sciences (Ethical Code is IR.TBZMED.REC.1400.575).
In silico investigation of DNA methylation in lung cancer

DNA methylation status of the FTH1 gene was initially analyzed using TCGA methylation datasets on lung cancer (TCGA-LUNG dataset). As a public-funded project, TCGA represents a comprehensive “atlas” of cancer genomic profiles from large cohorts. To evaluate FTH1 methylation status, the beta value for the cg24898753 probe overlapping with CpG islands within FTH1 promoter in lung cancer samples and normal samples was attained from TCGA-LUNG dataset (The Illumina HumanMethylation27 Bead Chip) using Xena Functional Genomics Explorer (https://xena.ucsc.edu/). Then, changes in FTH1 DNA methylation were compared between the two groups according to mean values.

DNA Extraction and bisulfite conversion

To extract genomic DNA, tissue samples were mashed using mortar and pestle in liquid nitrogen and then transferred rapidly into extraction lysis buffer. Then, samples were homogenized and DNA isolation was done by DNeasy Blood and Tissue Kit kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. After, extracted DNA qualification was determined at 260 nm and 280 nm absorbance wavelengths using the NanoDrop spectrophotometer (ThermoFisher Scientific Life Sciences, USA). Then, bisulfite modification was done to convert unmethylated cytosine to uracil except for the 5-methylcytosines.

Quantitative methylation specific polymerase chain reaction (PCR)

We use the quantitative methylation-specific PCR (q-MSP) to determine the DNA methylation status of FTH-1 and SHOX genes in experimental samples. To do so, we retrieved the sequence of CpG islands within FTH-1 and SHOX promoter from the UCSC genome browser (https://genome.ucsc.edu/). Then, using MethPrimer program (http://www. urogene.org/methprimer/), methylation-specific primers were designed, and q-MSP was performed in the Applied Biosystems Step One Plus Real-Time PCR System (USA) using 2X Real-Time PCR Master Mix (BioFACT™, South Korea). The reaction occurred under the following conditions: Pre-heating at 95 °C for 13 min, 45 cycles of denaturation for 10 s at 94 °C, 30 s annealing at 60 °C and 20 s extensions at 72 °C followed by a melting curve analysis. The comparative 2^(-ΔΔCt) method was used for the relative quantification of target gene methylation. The sequences of designed primers are shown in table 2.

Receiver operating characteristic (ROC) curve analysis

We used the ROC curve analysis to evaluate whether FTH-1 and SHOX2 DNA methylation status could be considered as the potential detection biomarkers to effectively discriminate NSCLC patients from healthy cases. Thus, the area under the curve (AUC) in TCGA-LUNG cohort and experimental tissue samples was estimated.

Statistical analysis

GraphPad Prism version 6.00 (GraphPad Software, San Diego, CA) was used for data analysis. In accordance with data distribution, the Mann-Whitney U test (TCGA-LUNG) and paired t-test (internal samples) were used to evaluate the statistical differences of DNA methylation between NSCLC tissue samples and adjacent normal specimens. ROC curve analysis was used to evaluate the probability of each miRNA as a biomarker (P < 0.05, mean ± SD).

Results

FTH-1 hypomethylation in correlated with NSCLC progression

FTH-1 DNA methylation was first investigated in the TCGA-LUNG dataset containing DNA methylation profiles of 277 lung cancer tissue samples and 168 noncancerous lung specimens. The results obtained based on cg24898753 probe
overlapping with FTH-1 promoter illustrated that FTH-1 is significantly ($P < 0.0001$) hypomethylated in NSCLC tissue samples as compared with normal lung tissue specimens (Figure 1). To further validate FTH-1 hypomethylation through lung tumorigenesis, a Q-MSP test was performed on our internal samples, including NSCLC tissue samples and adjacent normal specimens. As shown in figure 2, the results obtained from q-MSP also showed that FTH-1 is significantly ($P = 0.001$) hypomethylated through lung cancer progression (Figure 1). Furthermore, the association between clinic-pathological properties of patients and FTH-1 methylation was investigated in internal samples. It was shown that FTH-1 hypomethylation is significantly correlated with tumor stage ($P = 0.043$) and lymph node metastasis ($P = 0.029$). However, there was no significant relationship between FTH-1 methylation levels and other parameters including age and sex. The data are presented in table 3.

**SHOX2 hypermethylation in NSCLC samples**

SHOX2 DNA methylation was first investigated in the TCGA-LUNG dataset containing DNA methylation profiles of lung cancer tissue samples and noncancerous lung specimens. The results obtained based on cg17191178 probe overlapping with SHOX2 promoter illustrated that SHOX2 is significantly ($P < 0.0372$) hypermethylated in NSCLC tissue samples compared with normal lung tissue specimens (Figure 2). In our samples, the results from q-MSP indicated that SHOX2 exhibits significantly higher methylation levels in NSCLC samples compared with adjacent healthy tissues, as depicted in Figure 2. Besides, SHOX2 methylation levels was shown to be significantly correlated with tumor stage ($P = 0.031$) and lymph node metastasis ($P = 0.042$) in NSCLN patients. However, there was no significant relationship between SHOX2 methylation levels and other parameters including age and sex. The data are presented in table 3.

**High diagnostic value of FTH-1 and SHOX2 methylation in NSCLC**

To further examine whether aberrant methylation of FTH-1 and SHOX2 could be valuable diagnosis biomarkers in NSCLC, ROC curve analysis was performed using q-MSP results. As seen in Figure 3, the results implied that FTH-1 and SHOX2 methylation exhibit high potential as the detection biomarkers (AUC = 0.82, $P < 0.0001$ and AUC = 0.64, $P < 0.024$, respectively) to discriminate NSCLC patients from normal ones.

**Discussion**

This study evaluated the aberrant DNA methylation of FTH1 and SHOX2 in lung cancer progression. Firstly, FTH1 methylation as a biomarker for NSCLC was investigated using TCGA-LUNG datasets. The results showed that FTH1 is significantly hypomethylated in NSCLC samples compared with normal ones. FTH1 hypomethylation through lung tumorigenesis was further validated in a set of experimental samples, including 50 NSCLC tissue samples and 50 adjacent normal tissue samples, using the q-MSP technique method; showing a significant correlation between FTH1 methylation levels, tumor and lymph node metastasis. Moreover, ROC curve analysis indicates that FTH1 methylation has a biomarker potential in NSCLC patients (AUC = 0.82). Additionally, SHOX2 methylation status was also investigated in internal samples in the present study. Our results established that SHOX2, known as an important tumor suppressor gene, is significantly hypermethylated gene through NSCLC progression. Also, a significant correlation was found between SHOX2 methylation levels and clinical features, including lymph node metastasis and stage of
malignancy. Also, the diagnostic value of SHOX2 methylation for NSCLC was confirmed by ROC curve analysis, which estimated an AUC value equal to 0.64. Early diagnosis of lung cancer remains a critical need to improve treatment outcomes. Abnormal methylation has also been shown to be associated with tumor occurrence and development through abnormal gene expression which leads to dysregulation of downstream signaling pathways.\textsuperscript{18} Besides, growing studies have established that aberrant DNA methylation of various genes is correlated with tumor aggressiveness and progression,\textsuperscript{19,20} illustrating its significance as a diagnostic and prognostic target. Also, FTH1 plays key roles in a wide array of cellular processes, including cytokine signaling, adaptive immunity,\textsuperscript{21} and cell death.\textsuperscript{12} FTH1 has been previously illustrated in triple-negative breast cancer to participate in the activation of IFN α/β and IFN γ signaling.\textsuperscript{22} Furthermore, its upregulation was shown to affect neural progenitor cell migration, proliferation, and apoptosis, in vitro.\textsuperscript{23} FTH1 dysregulation was also found to be involved in the pathogenesis of various human malignancies, including lung, liver, and prostate cancers. Epigenetic silencing of FTH1 also could inhibit cell growth of Hep-G2 liver cancer cells; illustrating its significance in human cancers.\textsuperscript{24} Amjad et al. reveal that suppressing of FTH1 induces mammosphere formation and cell proliferation, which leads to high expression of cellular myelocytomatosis (c-MYC), and decreased sensitivity of breast cancer to chemotherapy.\textsuperscript{25} They also found that the upregulation of FTH1 reduces cell proliferation and growth via suppression of c-MYC oncogene.\textsuperscript{25} Also, Lu et al. indicated that suppressing of FTH-1 reduces prostate cancer metastasis via the downregulation of S100A4, S100A2, and S100P expression.\textsuperscript{26} Biamonte et al. revealed that suppression of FTH1 n K562 cells promotes the expression of some onco-miRNAs, and boosts chemoresistance in K562 and SKOV3 cells.\textsuperscript{27} Also, Li et al. found that the upregulation of FTH1P3 LncRNA increased the migration and invasiveness of NSCL via activating epithelial-mesenchymal transition.\textsuperscript{28} Liu et al. found circulating IncRNA FTH1P2 (exosome RNAs) in lung adenocarcinoma patient’s blood which was considerably correlated with the prognosis and diagnosis of NSCLC.\textsuperscript{29} As a member of the paired homeobox gene family short stature homeobox located at chr3q25.32, SHOX2 has been identified to be highly expressed in various malignancies. However, SHOX2 functions and involved molecular mechanisms through lung tumorigenesis are rarely known. Li et al. established that SHOX2 dysregulation may participate in lung cancer incidence, metastasis, and recurrence.\textsuperscript{30} Also, SHOX2 methylation levels were shown to be associated with the tumor stage in lung cancer malignancies and were higher in advanced stages of lung cancer patients.\textsuperscript{31} In another study, Zeng et al. found that miR-375 upregulation and SHOX2 hypermethylation led to worse pathological features in NSCLC patients. They also showed that SHOX2 methylation and upregulation of miR-375 together had better diagnostic worth than the single diagnosis.\textsuperscript{32} Also, Vo et al. indicated that methylation of SHOX2 is the acceptable marker to separate from benign malignant lung tissue in Vietnamese patients.\textsuperscript{33} Kneip et al. demonstrated that DNA methylation of SHOX2 could be used as a biomarker to recognize lung cancer patients from healthy groups at a sensitivity and specificity of 60% and 90% respectively.\textsuperscript{34} Feng et al. detected that 93.3% of NSCLC patients hypermethylated in SHOX2 gene in tumor tissue samples (83 from 89 NSCLC patients).\textsuperscript{35}
Given the limitations of this study, to get more precise outcomes and better understanding, we need further research with a higher number of patients and related genes with FTH-1 and SHOX2 to be used as a prognostic and diagnostic factor in lung cancer.

**Conclusion**

Given the high mortality rate of lung cancer, mostly due to prognosis, identification and validation of novel diagnostic biomarkers remain the constant need for the better management of this malignancy. Therefore, in the present study, FTH-1 and SHOX2 methylation levels was investigated in lung cancer. Taken together, our results imply that FTH-1 and SHOX2 exhibit aberrant DNA methylation levels through lung tumorigenesis, and they could be considered as valuable targets for the development of novel diagnostic application based on non-invasive methods such as liquid biopsy.

**Acknowledgements**

The authors appreciate the researchers of the Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

**Funding**

This study was supported by the Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Science, Tabriz, Iran.

**Authors’ Contribution**

S.T: Conceptualization, Writing - Original Draft; A.S: Study design, Writing - Original Draft, conducted literature searches and selected relevant articles; H.Z: Study design, Conducted the literature search, selected relevant articles, and critically analyzed the information and reviewed the final draft; M.A: Data gathering, Drafted specific sections of the manuscript; Sh.H: data gathering, Sample Collection, Methodology.; V.Z: Data gathering, Analyzed and synthesized information from selected articles, and participation in drafting; H.S.J: study design, drafting and reviewing the manuscript, Approved the final version of the manuscript; M.R: Project administration, Conceptualization and design of the work, writing review and editing;

All authors have read and approved the final manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Conflict of Interest**

None declared.

**References**


Table 1. Baseline data and clinicopathological characteristics of patients with lung cancer

<table>
<thead>
<tr>
<th>Number of samples</th>
<th>50</th>
<th>23 samples &lt;50</th>
<th>27 samples &gt;50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean)</td>
<td>56.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td>Female 24</td>
<td>Male 26</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td>Stage 2 23</td>
<td>Stage 3 25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stage 4 2</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td>Negative 21</td>
<td>Positive 29</td>
</tr>
</tbody>
</table>

Table 2. Primer sequencing

<table>
<thead>
<tr>
<th></th>
<th>Forward and reverse</th>
<th>Annealing temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTH_1</td>
<td>Forward:GATCCTGAGTATGGATGAA Reverse:CGTTTGCCATGCCAGAG</td>
<td>60</td>
</tr>
<tr>
<td>SHOX</td>
<td>Forward:GTCCGTAATCGTACGAATC Reverse:AATCGTGATCGGAAATCGCA</td>
<td>60</td>
</tr>
</tbody>
</table>

Table 3. Clinicopathological characteristics of patients Coloration with FTH_1 and SHOX2 genes

<table>
<thead>
<tr>
<th></th>
<th>FTH_1</th>
<th>SHOX2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>$P$ value:0.56</td>
<td>$P$ value:0.182</td>
</tr>
<tr>
<td>Sex</td>
<td>$P$ value:0.231</td>
<td>$P$ value:0.324</td>
</tr>
<tr>
<td>Stage</td>
<td>$P$ value:0.043</td>
<td>$P$ value:0.031</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>$P$ value:0.029</td>
<td>$P$ value:0.042</td>
</tr>
</tbody>
</table>
Figure 1. This figure shows the analysis of methylation levels of FTH-1 in NSCLC samples using q-MSP. The results showed that the gene is significantly hypomethylated in NSCLC tumors in comparison with normal adjacent tissues; $P < 0.05$. FTH-1 methylation status in TCGA-STAD. Comparison of FTH-1 overall methylation levels between NSCLC and normal samples using TCGA-STAD methylation cohort. FTH-1 shows significantly hypomethylated in NSCLC tumors ($**P < 0.0001$).

NSCLC: Non-small cell lung cancer; FTH-1: Ferritin Heavy Chain 1; q-MSP: Quantitative Methylation-specific PCR; TCGA-STAD: The Cancer Genome Atlas- Stomach adenocarcinoma

Figure 2. Analysis of SHOX2 methylation levels in NSCLC samples using q-MSP. The results show that the gene is hypermethylated in NSCLC tumors in comparison with normal adjacent tissues ($*P < 0.05$). SHOX2 methylation status in TCGA-STAD. Comparison of SHOX2 hypermethylation levels between NSCLC and normal samples using TCGA-STAD methylation cohort. SHOX2 shows significantly hypermethylated in NSCLC tumors ($*P < 0.05$).

NSCLC: Non-small cell lung cancer; SHOX2: Short stature homeobox 2; q-MSP: Quantitative methylation-specific PCR; TCGA-STAD: The Cancer Genome Atlas- Stomach adenocarcinoma
Figure 3. ROC curve analysis; A) ROC curve analysis was performed on NSCLC samples for FTH-1 that shows a promising diagnostic value. B) ROC curve analysis was performed on NSCLC samples for SHOX2 accuracy as a diagnostic biomarker for NSCLC as well.

ROC: Receiver operating characteristic; NSCLC: Non-small cell lung cancer; SHOX2: Short stature homeobox 2. q-MSP: Quantitative methylation-specific PCR; FTH-1: Ferritin Heavy Chain 1